Given the sparse data on circulating OPG and TRAIL and survival following a breast cancer diagnosis, we evaluated associations between postdiagnosis circulating OPG and TRAIL concentrations in relation to all-cause mortality, breast cancer-specific mortality, and recurrence-free survival overall and by hormone receptor status in a German population-based patient cohort study. The gene discussed is NR4A1; the disease is breast carcinoma.